Stay updated on HOPE-B: AMT-061 Clinical Trial
Sign up to get notified when there's something new on the HOPE-B: AMT-061 Clinical Trial page.

Latest updates to the HOPE-B: AMT-061 Clinical Trial page
- Check7 days agoChange DetectedThe page revision tag has been updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedAdded new data points and definitions for outcomes and safety, including Month 60 AFP levels, inflammatory markers, anti-AAV5 antibodies, vector DNA shedding, adverse events, and multiple FIX activity and bleeding endpoints with specified timepoints. Deleted older endpoints and measurement definitions (for example ABR calculation method, lead-in FIX consumption and activity metrics, and some lead-in/18-month timepoints) to align with updated study reporting.SummaryDifference3%

- Check36 days agoChange DetectedUpdated the site revision from v3.4.3 to v3.5.0; the page content and user workflows remain unchanged.SummaryDifference0.0%

- Check50 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing Revision: v3.4.2. The update does not modify study information, eligibility criteria, or results.SummaryDifference0.0%

- Check72 days agoChange DetectedThe footer now displays Revision: v3.4.2, replacing Revision: v3.4.1. This appears to be a minor system update with no impact on study content or user actions.SummaryDifference0.0%

- Check79 days agoChange DetectedPublications section updated: added the NEJM article 'Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B' (N Engl J Med, 2026 Jan 29; DOI 10.1056/NEJMoa2514332) and removed the NEJM article 'Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B' (Dec 7, 2025).SummaryDifference0.1%

Stay in the know with updates to HOPE-B: AMT-061 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HOPE-B: AMT-061 Clinical Trial page.